Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, announced yesterday that it has named Michael Tomsicek as its director.
Presently, Tomsicek is the chief financial officer of biopharmaceutical company, CRISPR Therapeutics. At Milestone he will also serve as chairman of the board's Audit Committee.
Tomsicek has more than 20 years of corporate and financial leadership experience to Milestone. Prior to joining CRISPR, he served as the chief financial officer of Abiomed. He has also served as chief financial officer at Cubist Pharmaceuticals, where he held various roles in financial operations, investor relations, and corporate strategy. During his tenure at Cubist, he participated in the transition of the company following its acquisition by Merck. He also served in a series of financial leadership positions at General Electric Healthcare, where he oversaw the global ultrasound business.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer